Nicardipine: Difference between revisions
(added page) |
No edit summary |
||
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Hypertension]]=== | |||
*PO: 20-40 mg q8hr, or 30-60mg (extended release) q12hr | *PO: 20-40 mg q8hr, or 30-60mg (extended release) q12hr | ||
*IV: 5 mg/hr by slow infution (50 ml/hr) | *IV: 5 mg/hr by slow infution (50 ml/hr) | ||
===Chronic Stable Angina=== | |||
*20-40 mg PO q8hr | *20-40 mg PO q8hr | ||
*Allow 3 days between dose increase | *Allow 3 days between dose increase | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Hypertension=== | |||
*0.5-3 mcg/kg/min IV | *0.5-3 mcg/kg/min IV | ||
*Not approved by FDA; limited date available | *Not approved by FDA; limited date available | ||
Revision as of 06:00, 30 July 2015
General
- Type: Calcium Channel Blocker
- Dosage Forms: Capsule, Infusion solution, Injectable solution
- Common Trade Names: Cardene
Adult Dosing
Hypertension
- PO: 20-40 mg q8hr, or 30-60mg (extended release) q12hr
- IV: 5 mg/hr by slow infution (50 ml/hr)
Chronic Stable Angina
- 20-40 mg PO q8hr
- Allow 3 days between dose increase
Pediatric Dosing
Hypertension
- 0.5-3 mcg/kg/min IV
- Not approved by FDA; limited date available
Special Populations
- Pregnancy Rating: Category C
- Lactation: Unknown wether drug is excreted in breast milk; avoid use
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 2-4 hr
- Metabolism: Metabolized in liver b CYP3A4 (first pass)
- Excretion: urine (60%), feces (35%)
- Mechanism of Action: